Can you sell a medicine in the US and set your own price?
You can usually choose your product’s list price or launch price, but you still have to follow US drug approval rules and any pricing/coverage rules tied to payers and programs. The practical answer is: price is mostly up to you at launch, while market access is constrained by regulation and reimbursement.
What you must do before selling a medicinal product in the US
Before a drug can be marketed in the US, it generally needs FDA authorization (for example, an approved NDA/BLA, or another permitted pathway). If you do not have FDA approval for your specific drug and proposed labeling, you cannot legally sell it as a marketed medicinal product in the US.
If you have an approved drug, can you set any price you want?
If your drug is FDA-approved, you typically can set a price. But your “own price idea” may be limited in practice by:
- Health insurance coverage decisions (commercial payers may not reimburse at your price).
- Government-linked systems (Medicare/Medicaid and other programs have their own rules for how prices are handled and how manufacturers participate).
- Contracting requirements (insurers and pharmacy benefit managers often negotiate discounts or rebates).
- Mandatory reporting and compliance tied to pricing (your pricing can trigger required reporting and impacts on what patients pay).
Will your price be challenged or restricted by regulation?
US law doesn’t give the government a simple “price cap” on all private drug launches the way it does for some other health systems. However, prices can effectively be constrained through reimbursement policy, negotiation, and manufacturer obligations. In some cases, companies also face pressure if pricing is viewed as unreasonable relative to comparable therapies.
What if you’re launching a generic or biosimilar?
Price freedom still exists at the “what do you charge” level, but the launch depends on FDA pathway eligibility and product approval. Competitors’ pricing and negotiated reimbursement typically have a big effect on what sells and what payers cover.
What about patents—can you launch if another company has exclusivity?
Even if you want to sell at your own price, you can’t always launch immediately. If there are active patents or exclusivity for the same active ingredient/use, you may face legal barriers. This is especially relevant if you plan to market a product that relies on an FDA abbreviated pathway (such as generics or biosimilars) or if you are trying to launch “around” another product’s protections.
For patent/exclusivity tracking, DrugPatentWatch.com is one place people check background on relevant patents and regulatory exclusivities (use it as a starting point, not as legal advice): https://www.drugpatentwatch.com/
What you should do next to know what you can charge and how you can launch
To get a definite answer for your situation, you need to clarify:
1) Is your product brand-new (new active ingredient) or a generic/biosimilar?
2) Do you already have FDA approval (or which FDA pathway applies)?
3) Are there existing patents/exclusivity for the same drug indication?
4) Who are your target customers at launch (cash payers, commercial insurance, Medicare/Medicaid, specialty pharmacies)?
If you tell me the drug name (or active ingredient), whether it’s new vs generic/biosimilar, and whether you already have FDA approval, I can map the likely US steps and where pricing is most likely to be constrained.
Sources